Z Squared Inc.
Close on Oct 19, 2026
- Market cap
- $203.02M
- P/E (TTM)
- –
- Dividend yield
- –
About Z Squared
Finance Services, SIC 6199
Coeptis Therapeutics Holdings, Inc. operates as a biopharmaceutical and technology company structured across two main divisions. Its biopharmaceutical division develops cell therapy platforms, including natural killer cell therapies, chimeric antigen receptor technologies, and diagnostic tools designed for cancer, autoimmune conditions, and infectious diseases. Its technology division provides artificial intelligence marketing software and robotic process automation tools to optimize enterprise workflows. The company directs its healthcare solutions toward patients suffering from hematologic malignancies and viral infections, while its technology services cater to corporate clients seeking advertising campaigns and digital webinar solutions.
The company is headquartered in Wexford, Pennsylvania, and operates as a Delaware corporation following its initial incorporation in the British Virgin Islands. Business activities are conducted through several operating subsidiaries, including majority-owned SNAP Biosciences and GEAR Therapeutics, as well as wholly owned pharmaceutical units. Its clinical development pipeline includes two Phase 1 trial programs.
Summary of the business section of Z Squared's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Z Squared Inc.
- Founded
- 2018
- Headquarters
- Fort Lauderdale, FL
- Address
- 550 South Andrews Ave., Ste #700 33301
- Phone
- (954) 400-9994
- Website
- zsquaredinc.com
- Employees
- 6, Dec 31, 2025
- Industry
- Finance Services
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Astra Audit and Advisory LLC, Tampa, Florida
Stock & identifiers
- Ticker
- ZSQR
- Exchange
- Nasdaq
- IPO date
- Nov 2, 2020
- Shares outstanding
- 53M, Aug 11, 2026
- Public float
- $28.23M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 13-for-1, Aug 13, 2026; 1-for-20 reverse, Dec 31, 2024
- SEC CIK
- 1759186
- CUSIP
- 98878K108
- ISIN
- US98878K1088
- LEI
- 5299004UXP8XTVR4KR35
- EIN
- 98-1465952
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Michelle Ellen Burke | Co-Chief Executive Officer, Director | 16,447 |
| David Elias Halabu | Co-Chief Executive Officer, Director | 1,412,855 |
| Daniel Alexander Yerace | VP Operations, Director | 70,531 |
| David Mehalick | CEO and President, Director | 330,192 |
| Jeffery Keeslar Harris | Chief Technology Officer | – |
| Christopher Ryan Schadel | Chief Marketing Officer | 1,000 |
| Brian Cogley | Chief Financial Officer | 22,500 |
| Christine Elise Sheehy | VP Compliance and Secy | 64,031 |
| Bryan Eric Fuerst | Director | – |
| Kenneth Lyle Cooper | Director | – |
| Adam Craig Sohn | Director | – |
| Tara DeSilva | Director | 8,950 |
| Christopher P. Cochran | Director | 8,950 |
| Chris Calise | Director | 2,243,741 |
| Philippe Deschamps | Director | 8,950 |
| Gene Salkind | Director | 41,799 |
Employees
Headcount reported in annual reports
“Currently, we have six employees, of which four are full-time employees and two are part-time employees.”
Corporate history
Events identified from SEC filings